Pulmonary function assessment post-left ventricular assist device implantation

被引:11
|
作者
Sajgalik, Pavol [1 ]
Kim, Chul-Ho [1 ]
Stulak, John M. [2 ]
Kushwaha, Sudhir S. [1 ]
Maltais, Simon [2 ]
Joyce, David L. [2 ,3 ]
Joyce, Lyle D. [2 ,3 ]
Johnson, Bruce D. [1 ]
Schirger, John A. [1 ]
机构
[1] Mayo Clin, Dept Cardiovasc Dis, 200 First St SW, Rochester, MN 55905 USA
[2] Mayo Clin, Dept Cardiovasc Surg, Rochester, MN USA
[3] Med Coll Wisconsin, Froedtert Hosp, Div Cardiothorac Surg, Milwaukee, WI 53226 USA
来源
ESC HEART FAILURE | 2019年 / 6卷 / 01期
基金
美国国家卫生研究院;
关键词
Continuous flow pumps; D-LCO; Pulmonary circulation; CONTINUOUS-FLOW; HEART-FAILURE; DIFFUSION ABNORMALITIES; CIRCULATORY SUPPORT; MUSCLE STRENGTH; LUNG-FUNCTION; PULSATILE; MORTALITY; CAPACITY; VOLUME;
D O I
10.1002/ehf2.12348
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aim The lungs-and particularly the alveolar-capillary membrane-may be sensitive to continuous flow (CF) and pulmonary pressure alterations in heart failure (HF). We aimed to investigate long-term effects of CF pumps on respiratory function. Methods and results We conducted a retrospective study of patients with end-stage HF at our institution. We analysed pulmonary function tests [e.g. forced vital capacity (FVC) and forced expiratory volume in 1 s (FEV1)] and diffusing capacity of the lung for carbon monoxide (D-LCO) from before and after left ventricular assist device (LVAD) implantation and compared them with invasive haemodynamic studies. Of the 274 patients screened, final study analysis involved 44 patients with end-stage HF who had CF LVAD implantation between 1 February 2007 and 31 December 2015 at our institution. These patients [mean (standard deviation, SD) age, 50 (9)years; male sex, n = 33, 75%] received either the HeartMate II (Thoratec Corp.) pump (77%) or the HeartWare (HeartWare International Inc.) pump. The mean (SD) left ventricular ejection fraction was 21% (13%). At a median of 237 days post-LVAD implantation, we observed significant D-LCO decrease (-23%) since pre-implantation (P < 0.001). Delta D-LCO had an inverse relationship with changes in pulmonary capillary wedge pressure (PCWP) and right atrial pressure (RAP) from pre-LVAD to post-LVAD implantation: Delta D-LCO to Delta PCWP (r = 0.50, P < 0.01) and Delta D-LCO to Delta RAP (r = 0.39, P < 0.05). We observed other reductions in FEV1, FVC, and FEV1/FVC between pre-LVAD and post-LVAD implantation. In mean (SD) values, FEV1 changed from 2.3 (0.7) to 2.1 (0.7) (P = 0.005); FVC decreased from 3.2 (0.8) to 2.9 (0.9) (P = 0.01); and FEV1/FVC went from 0.72 (0.1) to 0.72 (0.1) (P = 0.50). Landmark survival analysis revealed that Delta D-LCO from 6 months after LVAD implantation was predictive of death for HF patients [hazard ratio (95% confidence interval), 0.60 (0.28-0.98); P = 0.03]. Conclusions Pulmonary function did not improve after LVAD implantation. The degree of D-LCO deterioration is related to haemodynamic status post-LVAD implantation. The Delta D-LCO within 6 months post-operative was associated with survival.
引用
收藏
页码:53 / 61
页数:9
相关论文
共 50 条
  • [41] The Impact of Heart Failure Progression on Post-Left Ventricular Assist Device Survival: An Analysis of the INTERMACS Registry
    Maniar, Sanjay
    Naftel, David
    Myers, Susan
    Topkara, Veil K.
    Novak, Eric
    Ewald, Gregory
    Kirklin, James K.
    Mann, Douglas L.
    CIRCULATION, 2012, 126 (21)
  • [42] Noninvasive Assessment of Right Ventricular Function in Patients with Pulmonary Arterial Hypertension and Left Ventricular Assist Device
    Gautam Ramani
    Wengen Chen
    Sonika Patel
    Jean Judy
    Van-Khue Ton
    Current Cardiology Reports, 2019, 21
  • [43] Renal Function Changes Following Left Ventricular Assist Device Implantation
    Daimee, Usama A.
    Wang, Meng
    Papernov, Anna
    Sherazi, Saadia
    McNitt, Scott
    Vidula, Himabindu
    Chen, Leway
    Alexis, Jeffiey D.
    Kutyifa, Valentina
    AMERICAN JOURNAL OF CARDIOLOGY, 2017, 120 (12): : 2213 - 2220
  • [44] Noninvasive Assessment of Right Ventricular Function in Patients with Pulmonary Arterial Hypertension and Left Ventricular Assist Device
    Ramani, Gautam
    Chen, Wengen
    Patel, Sonika
    Judy, Jean
    Ton, Van-Khue
    CURRENT CARDIOLOGY REPORTS, 2019, 21 (08)
  • [45] NUTRITIONAL ASSESSMENT OF PATIENTS UNDERGOING LEFT VENTRICULAR ASSIST DEVICE IMPLANTATION
    Felpel, Kevin
    Palmese, Lidia
    Shapero, Mary
    Esbenshade, Jaclyn
    Urrutia, Luis
    Hamid, Syed
    Vest, Michael
    CRITICAL CARE MEDICINE, 2020, 48
  • [46] Phosphodiesterase-5 Inhibitor Therapy and Post-Left Ventricular Assist Device Outcomes The Significance of Uncertainty
    Houston, Brian A.
    CIRCULATION-HEART FAILURE, 2019, 12 (06)
  • [47] Treatment of Ventricular Assist Device Thrombus by Implantation of an Additional Left Ventricular Assist Device
    Ricklefs, Marcel
    Hanke, Jasmin S.
    Schmitto, Jan D.
    ARTIFICIAL ORGANS, 2018, 42 (04) : 464 - 465
  • [48] Stent implantation in a left ventricular assist device
    Alvarez Ramos, Raquel
    Andres Lalaguna, Luis Maria
    Diez Gil, Jose Luis
    REC-INTERVENTIONAL CARDIOLOGY, 2020, 2 (01): : 59 - 60
  • [49] Implantation of the HeartWare Left Ventricular Assist Device
    Slaughter, Mark S.
    SEMINARS IN THORACIC AND CARDIOVASCULAR SURGERY, 2011, 23 (03) : 245 - 247
  • [50] The Prognostic Value of Preoperative Pulmonary Function Testing in Patients Undergoing Left Ventricular Assist Device Implantation
    Seese, L.
    Aranda-Michel, E.
    Hickey, G.
    Keebler, M.
    Sciortino, C.
    Mathier, M.
    Kilic, A.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2020, 39 (04): : S36 - S37